SUMMARY Formalin fixed and paraffin wax embedded tissue from 85 well characterised cases of non-Hodgkin's lymphoma and Hodgkin's disease were studied using the avidin-biotin-peroxidase complex technique. Among the non-Hodgkin's lymphomas all cases of B cell lymphoma were reactive with L26, a monoclonal antibody which is as yet an unclustered pan B cell reagent, with the exception of pre-B cell acute lymphoblastic leukaemia and malignant lymphoma plasmacytic. Eighteen well characterised cases of T cell lymphoma, selected to include tumours previously shown to exhibit cross reactivity with antibodies to fixation resistant B cell related antigens, were similarly studied. Neoplastic cells in all but one case were unstained by L26. Twenty seven cases of Hodgkin's disease were also examined. In five cases all Reed-Sternberg cells and their variants were strongly stained by L26; only a proportion of Reed-Stemnberg cells and their variants were recognised in a further five cases.
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Monoclonal antibody L26 promises to be a valuable reagent for the diagnosis of malignant lymphoma in routinely fixed and paraffin wax embedded tissues. Its advantage lies in its sensitivity and greater B cell specificity than any of the B cell related reagents currently available for the study of malignant lymphoma in fixed tissues.
Until recently the immunophenotypic characterisation of malignant lymphoma has relied on the immunocytochemical demonstration of leucocyte antigens in cryostat sections of fresh frozen tissue. An increasing range of novel monoclonal antibodies, however, is now available, which facilitate the diagnosis of malignant lymphoma in formalin fixed and paraffin wax embedded tissues. Several of these novel antibodies recognise B cell related antigens that are resistant to fixation. Most bind to lineage restricted epitopes on the leucocyte common molecule, 1 -3 while others identify antigens, which although not wholly restricted to leucocytes, indicate a B cell lineage in known lymphoid tissues.4-5 Anti-HLA-DR67 and antibodies to HLA-DR-like moieties4 have been used to assign a B cell phenotype but these are unreliable, especially in the diagnosis of large cell lymphomas which may express class II antigens Accepted for publication 18 June 1987 independent of their phenotype. Despite the number of antibodies available there is a considerable degree of cross lineage reactivity, particularly among the leucocyte common restricted group, necessitating the use of extensive antibody panels to avoid assigning erroneous phenotypes to cases of lymphoma. [8] [9] [10] Monoclonal antibody L26 identifies mature B lymphocytes.1 1 13 Although submitted to the second and third leucocyte typing workshops, L26 is as yet unclustered. In sodium dodecyl sulphatepolyacrylamide gel electrophoresis L26 precipitates an antigen with a major 33 kd molecular weight component, together with a minor 30 kd component.'2 Unlike other B cell restricted leucocyte antibodies, L26 recognises an epitope which is resistant to conventional formalin fixation. In this study we evaluated L26 on a panel of malignant lymphomas fixed in formalin and embedded in paraffin wax and contrasted its reactivity with that obtained using other antibodies to B cell related antigens resistant to fixation. 1405 
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Material and methods
Formalin fixed and paraffin wax embedded tissue from 85 cases of Hodgkin's disease and nonHodgkin's lymphoma were obtained from the surgical pathology files of the department of histopathology of this hospital. The 40 cases of B cell lymphoma were classified according to the Kiel classification'5; 18 cases of T cell lymphoma were categorised by the scheme of Stansfeld'7; and 27 cases of Hodgkin's disease were classified by the scheme of Lukes and Butler.'6 All but five of the cases of nonHodgkin's lymphoma had previously been characterised in frozen sections using a panel of monoclonal antibodies. In five cases of B cell lymphoma (two cases of malignant lymphoma plasmacytic, two cases of malignant lymphoma centroblastic, one case of Burkitt's lymphoma) immunoglobulin light chain restriction had been shown in paraffin sections.
Normal tonsils from routine tonsillectomies and non-specific reactive lymph nodes were also studied to evaluate L26 staining in normal tissue and to assess immunoreactivity after different fixation protocols. 
Discussion
The range of monoclonal antibodies providing phenotypic data on malignant lymphoma in routinely processed tissue has recently expanded. Of greatest value in diagnosis are those antibodies capable of assigning a T, B, or macrophage phenotype, most of which identify lineage restricted moieties of leucocyte common antigen. Broad panels of these reagents combined with anti-immunoglobulins and nonphenotype associated reagents now permit accurate phenotyping of malignant lymphoma in routinely processed tissue. 8 -10 21 Antibodies identifying lineage restricted leucocyte common moieties bind to epitopes derived by variable splicing of the pre-mRNA. Thus members of the CD45R cluster' 2and MB13 recognise B lymphocytes and some B progenitors, while UCHL1 recognises T lymphocytes, macrophages, and myeloid cells.2223 None of these reagents is entirely specific, however, as the B cell related antibodies recognise a proportion of normal and neoplastic T cells' 289 and similarly, UCHL1 has been noted to stain sporadic cases of B cell lymphoma.'0 Two further T cell related antibodies MTI3 and L6024 are closely related to this leucocyte common restricted group and have also been shown to react with some normal B lymphocytes and a proportion of cases of B cell lymphoma.'0 24 As we have shown in this study, where a tumour exhibits cross lineage reactivity it usually occurs with more than one of these reagents. Antibodies LN14 and MB25 differ from the leucocyte common group by recognising a wide range of non-lymphoid tissues in addition to B lymphocytes. In lymphoid tissue immunoreactivity with LNl is restricted to subsets of B cells4 10 whereas MB2 is a sensitive pan-B reagent.5 10 LNl exhibits little cross lineage reactivity but MB2 does bind to some T cell lymphomas.5
A recent addition to the range of antibodies to fixation resistant antigens is KiB3.25 The antigen group.bmj.com on January 11, 2018 -Published by http://jcp.bmj.com/ Downloaded from identified is restricted to lymphoid cells and is found on mature B lymphocytes, with the notable exception of splenic marginal zone cells. 13 As we have shown in this study some reactivity with T cell lymphoma is also observed with this antibody.
In spite of the drawbacks with many of these antibodies, a confident and reliable immunophenotypic diagnosis can be established in most cases of nonHodgkin's lymphoma, provided that a broad panel of antibodies is used. 9 10 21 In this study we have clearly shown that it is possible to show reliably the B cell nature of nonHodgkin's lymphoma in routinely fixed and wax embedded tissue using L26. With the exception of common acute lymphoblastic leukaemia and malignant lymphoma plasmacytic, neoplastic cells in all instances of B cell lymphoma, including those reactive with MTI, were stained by L26. Furthermore, we have recently encountered a case of B cell lymphoma (malignant lymphoma immunoblastic) reactive with UCHLI, and even in this instance L26 staining was positive. Among our T cell lymphomas which cross reacted with leucocyte common B cell related antibodies or MB2, in only one case were the neoplastic cells reactive with L26. This expression of a B cell antigen by a T cell neoplasm is interesting. Rare instances of well characterised T cell lymphoma giving aberrant reactivity with B cell restricted antibodies have been reported, and these were all large cell T cell neoplasms.2627 With the exception of such unusual cases, L26 can be regarded as a specific marker of B cell differentiation in non-Hodgkin's lymphoma. Both its sensitivity and greater specificity compared with that of the other B cell related markers cited here permit its use as a single reagent. Thus recourse to a broader panel of B cell related antibodies is only rarely required. Although B cell specific, the L26 antigen is not expressed early in B cell ontogeny,13 being absent in pre-B acute lymphoblastic leukaemia and common acute lymphoblastic leukaemia. It is therefore advisable to use L26 in combination with a CD45R as this will increase the diagnostic yield in primitive B cell neoplasms.
The reactivity of L26 with Reed-Sternberg cells is noteworthy. The strong reactivity observed in lymphocyte and histiocyte predominant Hodgkin's disease supports the view of many workers that this subtype is indeed a B cell proliferation.28 29 In conclusion, we have shown that L26 offers a more reliable indication of B cell phenotype in routinely processed cases of non-Hodgkin's lymphoma than is currently possible with restricted leucocyte common antibodies LNI or MB2. The search for other reagents to well characterised cluster determinants or to individual molecular weight moieties of the leucocyte common molecule, as epitomised by UCHL1, will further enhance the diagnostic accuracy of malignant lymphoma in routinely fixed and processed tissues.
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